Virax Biolabs Group Limited
VRAX · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $6 | $156 | $9 | $0 |
| % Growth | -96% | 1,727.1% | – | – |
| Cost of Goods Sold | $59 | $106 | $10 | $0 |
| Gross Profit | -$53 | $51 | -$1 | $0 |
| % Margin | -838.2% | 32.3% | -15.9% | – |
| R&D Expenses | $1,780 | $1,562 | $397 | $434 |
| G&A Expenses | $4,330 | $4,595 | $5,308 | $1,286 |
| SG&A Expenses | $4,330 | $4,595 | $5,334 | $1,300 |
| Sales & Mktg Exp. | $0 | $0 | $27 | $14 |
| Other Operating Expenses | $0 | $390 | $0 | $0 |
| Operating Expenses | $6,110 | $6,547 | $5,731 | $1,734 |
| Operating Income | -$6,163 | -$6,496 | -$5,733 | -$1,734 |
| % Margin | -97,344.8% | -4,153.3% | -66,963.7% | – |
| Other Income/Exp. Net | -$41 | -$243 | $275 | -$16 |
| Pre-Tax Income | -$6,204 | -$6,739 | -$5,458 | -$1,750 |
| Tax Expense | -$137 | $0 | $0 | $0 |
| Net Income | -$6,061 | -$6,734 | -$5,457 | -$1,709 |
| % Margin | -95,739.2% | -4,304.8% | -63,748.3% | – |
| EPS | -1.96 | -3.36 | -5.13 | -1.5 |
| % Growth | 41.7% | 34.5% | -242% | – |
| EPS Diluted | -1.95 | -3.36 | -5.13 | -1.5 |
| Weighted Avg Shares Out | 3,097 | 2,006 | 1,063 | 1,137 |
| Weighted Avg Shares Out Dil | 3,104 | 2,006 | 1,063 | 1,137 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $15 |
| Interest Expense | $58 | $27 | $15 | $15 |
| Depreciation & Amortization | $343 | $103 | $0 | $1,734 |
| EBITDA | -$5,802 | -$6,609 | -$5,442 | -$1 |
| % Margin | -91,649.5% | -4,225.3% | -63,570.7% | – |